Highlights

  • Neurizon Therapeutics has completed a Placement and launched a Share Purchase Plan to eligible shareholders, with the proceeds supporting the company's funding position through to the anticipated topline results from the HEALEY ALS Platform Trial in late Q2 2027.
  • The company has redeemed all remaining convertible notes held by Obsidian, simplifying the Capital Structure and removing the potential dilution uncertainty that those instruments created.
  • NUZ-001, the company's lead investigational oral small molecule, is currently being evaluated in the Phase 2/3 HEALEY ALS Platform Trial, which enrolled 250 participants in under five months — a record for the platform.
  • FDA Type C feedback has indicated that the HEALEY Regimen I study has the potential to serve as a single registrational study, subject to substantial evidence of effectiveness, providing a clearer regulatory pathway for the company.

Neurizon Therapeutics Limited (ASX:NUZ) is an ASX-listed late clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company's lead investigational therapy, NUZ-001, is an oral small molecule currently being evaluated in the HEALEY ALS Platform Trial, a Phase 2/3 study for the treatment of amyotrophic lateral sclerosis, the most common form of motor neurone disease. On 5 November 2026, Neurizon hosted a Shareholder webinar to provide an overview of its recently completed capital raise, the launch of a Share Purchase Plan for eligible shareholders, and the rationale for redeeming the remaining convertible notes previously held by Obsidian. The presentation also covered the company's key upcoming clinical and corporate milestones.

Capital Structure Simplification and the Share Purchase Plan

The company completed a placement to new and existing institutional, sophisticated, and professional investors, with the proceeds intended to maintain Neurizon's funded status through to the anticipated topline readout from the HEALEY trial. The placement shares were offered alongside one free option per new share, exercisable at a higher price than the placement price and expiring 18 months from issue, subject to shareholder approval. A Share Purchase Plan was also launched, enabling eligible shareholders to participate at the same price as the placement, without brokerage, up to a defined maximum per holder.

A central element of the capital raise rationale was the Redemption of all remaining convertible notes held by Obsidian. The company highlighted that the existence of these instruments had created uncertainty around the capital structure, particularly regarding the potential for future dilution through note conversions. By redeeming the notes for cash rather than allowing conversion into shares, Neurizon removed this overhang entirely. The company noted that it had observed a meaningful share price recovery following a previously agreed standstill with Obsidian, and that simplifying the capital structure was expected to allow better market recognition of its clinical positioning going into the pivotal topline readout.

NUZ-001 and the HEALEY ALS Platform Trial

NUZ-001 is an oral, once-daily investigational small molecule with preclinical evidence suggesting effects on cellular protein clearance pathways associated with neurodegeneration. It is currently being evaluated in the HEALEY ALS Platform Trial as Regimen I, a 250-participant randomised Phase 2/3 study conducted across a network of 78 sites in the United States, led by Mass General Brigham. The trial enrolled its full complement of 250 participants in under five months, which the company described as a record enrolment pace within the HEALEY platform. Participants are randomised in a three-to-one ratio.

The company anticipates topline results from the trial in late Q2 2027. This readout is characterised by management as the defining event for the company's near-term development trajectory, as it will produce the first randomised efficacy data for NUZ-001. Ahead of this milestone, FDA Type C feedback has indicated the potential for Regimen I to serve as a single registrational study, subject to substantial evidence of effectiveness, which may simplify the regulatory pathway to a potential commercial application. Additionally, an Expanded Access Program for up to 200 participants, funded by the National Institutes of Health, is being prepared, which is expected to provide additional real-world safety and tolerability data alongside the trial.

Key Takeaways

Neurizon Therapeutics enters the final stretch before its pivotal HEALEY trial topline readout in a position it characterises as fully funded and with a meaningfully simplified capital structure following the Obsidian note redemptions. The Share Purchase Plan provides existing shareholders with an opportunity to participate in the raise on the same terms as institutional investors. The key upcoming milestones — including the first HEALEY Regimen I participant completing the randomised treatment phase, early Expanded Access Program enrolments, and Manufacturing and regulatory workstreams — are all in progress. The late Q2 2027 topline result will be the most significant near-term event for the company, with its outcome expected to inform decisions on regulatory strategy, potential partnering arrangements, and future commercial direction for NUZ-001.